Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: The present invention relates to a method of debugging a targeted area or the whole network-on-chip (NOC) (101), whereby said targeted area or the whole NOC is triggered to enter into a freeze state before capturing of the state of the targeted area or the whole NOC (101) and unloading of the debug information, before finally said targeted area or the whole NOC is triggered to enter into an unfreeze state to allow forward progress to resume, using existing buffer storage, thus allowing user to debug and identify the source of issue without requiring a significant amount of extra storage.

Abstract: A memory controller system (and method of pre-scheduling memory transaction) for a storage device comprising a linked-list controller; a plurality of command buffers to store read commands or write commands, and an arbiter to issue command. Each command buffer containing variables set by the linked-list controller. The linked-list controller is configured to execute commands in sequence independent of logical command buffer sequence. The command buffer is configured to support read commands with maximum number of write commands. The linked-list controller is configured to merge multiple write commands that are going to the same address and snarfs read commands from write commands if both commands are going to the same address and the read commands that are snarfed are loaded into a separate command buffer. The variables contained in each of the command buffer indicates status and dependency of the command buffer to create a link forming a command sequence.

Abstract: Methods for improving bioavailability and solubility of taxanes provided as solids in compressed tablet form are described. Compressed tablets containing a high proportion of a taxane are prepared using an amorphous solid dispersion in combination with a polymer carrier and a surfactant. Oral bioavailability of taxanes following ingestion is high, and supersaturating concentrations of the taxane are maintained in gastric fluids for an extended period of time.

Abstract: A memory controller system (and method of pre-scheduling memory transaction) for a storage device comprising a linked-list controller; a plurality of command buffers to store read commands or write commands, and an arbiter to issue command. Each command buffer containing variables set by the linked-list controller. The linked-list controller is configured to execute commands in sequence independent of logical command buffer sequence. The command buffer is configured to support read commands with maximum number of write commands. The linked-list controller is configured to merge multiple write commands that are going to the same address and snarfs read commands from write commands if both commands are going to the same address and the read commands that are snarfed are loaded into a separate command buffer. The variables contained in each of the command buffer indicates status and dependency of the command buffer to create a link forming a command sequence.

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: The inventive subject matter provides compositions and methods for producing high dose, high bioavailability oral taxane compositions. Oral taxanes are prepared as an amorphous solid dispersion, and can be provided in a compressed tablet form. Surprisingly oral bioavailability of taxanes prepared and provided in this matter is high, even in the absence of surfactants.

Abstract: The present disclosure provides for adaptive scheduling of memory refreshes. One embodiment relates to a method of adapting an initial refresh sequence. In this method, flow and blockage scores for each refresh sequence of a plurality of refresh sequences are obtained and stored in an array of scores. An initial refresh sequence is selected in a way that favors a high flow score and a low blockage score. Another embodiment relates to a method of adapting a current refresh sequence. Current flow and blockage scores are obtained and stored for the current refresh sequence. The current flow and blockage scores are used to update (by averaging, for example) the existing flow and blockage scores for the current refresh sequence. The next refresh sequence is then chosen from amongst a plurality of refresh sequences in a way that favors a high flow score and a low blockage score.

Abstract: The present disclosure provides for adaptive scheduling of memory refreshes. One embodiment relates to a method of adapting an initial refresh sequence. In this method, flow and blockage scores for each refresh sequence of a plurality of refresh sequences are obtained and stored in an array of scores. An initial refresh sequence is selected in a way that favors a high flow score and a low blockage score. Another embodiment relates to a method of adapting a current refresh sequence. Current flow and blockage scores are obtained and stored for the current refresh sequence. The current flow and blockage scores are used to update (by averaging, for example) the existing flow and blockage scores for the current refresh sequence. The next refresh sequence is then chosen from amongst a plurality of refresh sequences in a way that favors a high flow score and a low blockage score.

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: The present disclosure provides for adaptive scheduling of memory refreshes. One embodiment relates to a method of adapting an initial refresh sequence. In this method, flow and blockage scores for each refresh sequence of a plurality of refresh sequences are obtained and stored in an array of scores. An initial refresh sequence is selected in a way that favors a high flow score and a low blockage score. Another embodiment relates to a method of adapting a current refresh sequence. Current flow and blockage scores are obtained and stored for the current refresh sequence. The current flow and blockage scores are used to update (by averaging, for example) the existing flow and blockage scores for the current refresh sequence. The next refresh sequence is then chosen from amongst a plurality of refresh sequences in a way that favors a high flow score and a low blockage score.

Abstract: A dynamic braking system for an electric power system includes a switching device coupled to an electrical conductor. The switching device is configured to open and close with a plurality of predetermined frequencies. The dynamic braking system also includes an inductive device coupled to the switching device. The power losses of the inductive device are at least partially a function of the plurality of predetermined frequencies. The dynamic braking system further includes a dynamic braking controller coupled to the switching device. The dynamic braking controller is configured to open and close the switching device with at least one of the predetermined frequencies to dissipate electric power from the electrical conductor at a predetermined rate by regulating the power losses of the inductive device as a function of the predetermined frequencies.

Abstract: Embodiments of techniques and systems for protected access to virtual memory are described. In embodiments, a protected memory management architecture (“PMMA”) may be configured to control accesses to protected physical memory. The PMMA may provide a protected virtual memory window for dynamic allocation of protected memory regions. During forward translation of virtual memory addresses, the PMMA may check a region ID of a process before allowing access. During reverse translation of a physical memory address, the PMMA may prevent accesses to protected physical memory addresses. The PMMA may also dynamically allocate physical memory to protected memory regions in virtual memory and may authenticate the physical memory as available before allocation. Other embodiments may be described and claimed.

Abstract: A dynamic braking system for an electric power system includes a switching device coupled to an electrical conductor. The switching device is configured to open and close with a plurality of predetermined frequencies. The dynamic braking system also includes an inductive device coupled to the switching device. The power losses of the inductive device are at least partially a function of the plurality of predetermined frequencies. The dynamic braking system further includes a dynamic braking controller coupled to the switching device. The dynamic braking controller is configured to open and close the switching device with at least one of the predetermined frequencies to dissipate electric power from the electrical conductor at a predetermined rate by regulating the power losses of the inductive device as a function of the predetermined frequencies.

Abstract: Embodiments of techniques and systems for protected access to virtual memory are described. In embodiments, a protected memory management architecture (“PMMA”) may be configured to control accesses to protected physical memory. The PMMA may provide a protected virtual memory window for dynamic allocation of protected memory regions. During forward translation of virtual memory addresses, the PMMA may check a region ID of a process before allowing access. During reverse translation of a physical memory address, the PMMA may prevent accesses to protected physical memory addresses. The PMMA may also dynamically allocate physical memory to protected memory regions in virtual memory and may authenticate the physical memory as available before allocation. Other embodiments may be described and claimed.